When was Curis founded?

Curis was founded in 2000 and raised its 1st funding round 5 years after it was founded.

Where is Curis located?

Curis is headquartered in Lexington, United States. It is registered at Lexington,Massachusetts.

How many employees does Curis have?

As of May 31, 2026, the latest employee count at Curis is 154.

Is Curis a funded company?

Curis is a funded company, having raised an undisclosed amount across 6 funding rounds to date. The company's 1st funding round was a $***** Post IPO round, raised on Apr 14, 2005.

When was the latest funding round of Curis?

Curis' latest funding was a $***** Conventional Debt round on Apr 06, 2017, with participation from 1 investor.

What is the annual revenue of Curis?

Annual revenue of Curis is between $1M and $10M as on Dec 31, 2025

Where does Curis rank among its competitors?

Curis ranks 595th amongst 3261 active competitors, of which 1122 are funded. It stands 11th in terms of total funding among its competitors. The most recent competitor to raise funding was Immuneel, which secured $10.5M in Jun, 2026.

Who are the top competitors of Curis?

Curis' top competitors include Jazz Pharmaceuticals, Sana Biotechnology and Senti Bio. Among them, Immuneel secured the most recent funding round in June, 2026.

Curis - 2026 Company Profile, Team, Funding, Competitors & Financials

Company Details

Developer of therapeutics by targeting different signaling pathways to treat multiple cancers. The Company's lead drug candidate, CUDC-907, is an orally available, small-molecule inhibitor of histone deacetylase (HDAC) and phosphatidylinositol-3-kinase (PI3K) enzymes. The product pipeline includes CA-170 (PD-L1/VISTA antagonist), CA-4948 (IRAK4 kinase inhibitor). Other preclinical programs in collaboration with Aurigene include small molecule antagonists of the PD-L1 and TIM3 immune checkpoints. The Hedgehog pathway inhibitor Erivedge (vismodegib) was developed in collaboration with Genentech and is being commercialized by Genentech and Roche for the treatment of advanced basal cell carcinoma (BCC). Erivedge is currently approved for use in patients with advanced BCC in the US, EU, and several other countries. Roche and Genentech are also continuing the development of Erivedge including in less severe forms of BCC as well as in other diseases including in idiopathic pulmonary fibrosis, or IPF, and myelofibrosis.

Website: www.curis.com/
Registered Address: Lexington,Massachusetts

Key Metrics

Founded Year

2000

Location

Lexington, United States

Stage

Public

Latest Funding Round

Conventional Debt, Apr 06, 2017, $*****

Investors

HealthCare Royalty Partners & 4 more

Ranked

595^th among 3261 active competitors

Annual Revenue

$1M - $10M as on Dec 31, 2025

Employee Count

154 as on May 31, 2026

Similar Companies

Jazz Pharmaceuticals & 2977 more

Exit Details

Public

View Curis' full profile

Curis is associated with 2 legal entities given below:

Legal Entity Name	Date of Incorporation	Revenue	Latest Employee Count	Documents
CURIS INC CIN: 1108205 , United States, Active	Feb 13, 2000	$1M - $10M (As on Dec 31, 2025)	-	-
CURIS, INC. CIN: 43505116 , Belgium, Active	Dec 31, 1999	-	60 (As on Dec 31, 2021)	-

Curis got listed on Aug 04, 2000.

Click here to take a look at Curis's IPO in detail

Curis has raised funding over 6 rounds. Its first funding round was on Apr 14, 2005. Its latest funding round was a Conventional Debt round on Apr 06, 2017 for $*****. 1 investor participated in its latest round. Curis has 5 institutional investors.

Here is the list of recent funding rounds of Curis:

Filter this list

Date of Funding	Funding Amount	Round Name	Post-Money Valuation	Revenue Multiple	Lead Investors	Other Investors
Apr 06, 2017	6571950	Conventional Debt	9331192	5159749	1062828	1579025
Mar 02, 2015	6524625	Post IPO	4085539	1828853	4119444	9463744
Dec 12, 2012	4750046	Venture Debt	9178907	1232641	2120488	Pharmakon Advisors

Access funding benchmarks and valuations. Sign up today!

View details of Curis's funding rounds and investors

The founders of Curis are Curis World and Jim Curis.

Here are the details of Curis' key team members:

Curis World: Co-Owner of Curis.
Jim Curis: Owner of Curis.

View details of Curis's Founder profiles and Board Members

Curis' employee count trend

Curis has 154 employees as of May 26. Here is Curis's employee count trend over the years:

Uncover Curis' growth story! Sign up today!

Access Tracxn on any website

Our Google Chrome extension lets you view company details while browsing their websites

Install Tracxn Extension

Top competitors of Curis include Jazz Pharmaceuticals, Sana Biotechnology and Senti Bio. Here is the list of Top 10 competitors of Curis, ranked by Tracxn score:

Rank	Company Details	Short Description	Total Funding	Investors	Tracxn Score
1st	Jazz Pharmaceuticals 2003, Dublin (Ireland), Public	Developer of novel biopharmaceutical medicines for unmet medical needs	$265M	Versant Ventures, Prospect Venture Partners ... & 14 others	82/100
2nd	Sana Biotechnology 2018, Seattle (United States), Public	Developer of engineered cell therapies for treating various human diseases	$821M	Baillie Gifford, PSP Investments & 17 others	75/100
3rd	Senti Bio 2016, San Francisco (United States), Public	Developer of cell and gene therapies for patients living with incurable diseases	$158M	Celadon Partners, New Enterprise Associates ... & 30 others	72/100
4th	Ideaya Biosciences 2015, San Francisco (United States), Public	Developer of oncology-focused precision medicine using molecular diagnostics	$157M	BVF Partners, Boxer Capital & 15 others	72/100
5th	Sutro Biopharma 2003, United States, Public	Developer of antibody-based therapeutics for cancer therapy	$175M	Skyline Ventures, SV Health Investors & 17 others	72/100
6th	Syndax 2005, Waltham (United States), Public	Developer of targeted therapies for the treatment of cancer	$198M	Fidelity Investments, Domain Associates & 19 others	72/100
7th	Karyopharm 2008, Newton (United States), Public	Biopharmaceutical company focused on developing and commercializing innovative cancer therapies	$98.4M	Foresite Capital, Avidity Partners & 16 others	71/100
8th	Moderna 2010, Cambridge (United States), Public	Developer of mRNA-based therapeutics for a wide range of diseases	$2.78B	Merck, AstraZeneca & 32 others	71/100
9th	C4 Therapeutics 2016, Cambridge (United States), Public	Developer of small molecule drugs for treating cancer	$223M	Cobro Ventures, Perceptive Advisors & 27 others	71/100
10th	Immuneel 2018, Bengaluru (India), Series B	Developer of T-cell therapies for the treatment of cancer	$49.8M	True North, Khosla Ventures & 23 others	71/100
595th	Curis 2000, Lexington (United States), Public	Developer of therapeutics by targeting different signaling pathways to treat multiple cancers	-	HealthCare Royalty Partners, Genentech & 3 others	50/100